je.st
news
Tag: advanced
LANXESS Highlighting Advanced New Red Pigments at Eastern Coatings Show\n
2015-06-02 07:00:00| Coatings World Breaking News
Tags: advanced
red
shown
eastern
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review
2015-06-01 22:34:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-001 Data Served as the Basis for U.S. FDA Filing and Breakthrough Therapy Designation in Advanced NSCLC Across Histologies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on or after platinum-containing chemotherapy and an FDA-approved therapy for EGFR or ALK genomic tumor aberrations, if present. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
application
license
New Findings Show Durable Anti-Tumor Activity with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status
2015-05-29 20:06:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Results from KEYNOTE-012, the First and Largest Study to Date of an Anti-PD-1 Therapy in Head and Neck Cancer, to be Presented at 2015 ASCO Annual Meeting KEYTRUDA Monotherapy Achieved Overall Response Rate of 25 Percent in Heavily Pre-treated Patients Merck is Advancing a Broad Head and Neck Clinical Program for KEYTRUDA with Five Clinical Trials, Across Multiple Lines of Therapy and in Combination with Other Agents KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new investigational data evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from the KEYNOTE-012 Phase 1b study in 132 pre-treated patients with recurrent or metastatic head and neck cancer, regardless of PD-L1 expression status. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: show
advanced
status
head
Advanced Mezzanine Card features quad SATA III SSD module.
2015-05-29 14:31:06| Industrial Newsroom - All News for Today
Featuring mid-size, single-module design, Model AMC623 is equipped with four 1.8 in. SATA III drives for nearly 2 TB of storage. Four drives can provide 6 Gbps data rate which is routed to backplane via x2 PCIe lanes. Compliant to AMC.1 specification, advanced mezzanine card supports RAID 0, 1, and 10 for striping and mirroring options.
Tags: advanced
features
card
iii
Fabrico Medical to Exhibit Advanced Medical Fabrication Capabilities at the 2015 MD&M East Show
2015-05-29 12:31:08| Industrial Newsroom - All News for Today
Rochester, NY Fabrico Medical, a provider of custom manufacturing services and converter of thin flexible materials for the design-to-manufacture of medical devices and disposables, announces its participation in the 2015 MD and M East Show, Booth #743, June 9-11, 2015, at Jacob K. Javits Convention Center, New...
Tags: show
advanced
east
medical
Sites : [195] [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] [213] [214] next »